Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “INHALATION THERAPY”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,063 records · Page 59Linked to original sources
PubMedDate not supplied

Use of biological markers of airway inflammation to detect the efficacy of nurse-delivered asthma education.

OBJECTIVE: The purpose of this study was to determine whether analysis of the constituents of induced sputum could be used to document the efficacy of a nurse-delivered patient education intervention and whether changes in the biological markers of inflammation in sputum would correlate with improvements in pulmonary function and symptoms. DESIGN: The study design was prospective, open trial with repeated measures. SETTING: The study took place at a West Coast academic medical center laboratory. SUBJECTS: Subjects included 12 nonsmoking persons with asthma, ages 23 to 51 years, on prescribed daily anti-inflammatory inhaled therapy who had not required oral prednisone in the previous 4 weeks of enrollment. METHOD: The effect of one 30-minute asthma education session on spirometry, peak flow, symptoms, and biological markers of inflammation in sputum was tested for 8 weeks to determine whether biological markers reflect the efficacy of educational interventions. RESULTS: Mean symptom scores decreased and lung function increased slightly over 8 weeks. Markers of eosinophil degranulation decreased by 50% and albumin by 25% from baseline to 8 weeks. Eosinophil percentages dropped 20% over time but did not change consistently at all time points. Clinical markers of asthma control correlated in the low-to-moderate range with biological markers of airway inflammation. CONCLUSION: The results of this study show the effects of a patient education intervention can be detected in both clinical and biological outcomes. Individual education may influence self-care of asthma including adherence to inhaled corticosteroid therapy and thereby suppress airway inflammation.

Adult↗
PubMed2005

Induced nitric oxide impairs relaxation but not contraction in endotoxin-exposed rat pulmonary arteries.

BACKGROUND: Many patients with severe acute lung injury do not respond to nitric oxide (NO) inhalational therapy with alleviation of pulmonary arterial hypertension and hypoxemia, so this treatment remains controversial. MATERIALS AND METHODS.: We investigated in endotoxin-exposed Wistar rat pulmonary arteries whether endogenous NO alters contractile and relaxing responses, by electrochemical NO and isometric force measurements. RESULTS: Receptor-independent contraction was similar in control and endotoxin-exposed arteries, while thromboxane analogue (TxA)-dependent contraction was less in the latter. Neither non-selective NO synthase (NOS) inhibition by N(G)-nitro-l-arginine (l-NA) or selective inducible-NOS2 inhibition by aminoguanidine (AG) improved TxA-induced contraction in endotoxin-exposed arteries. Acetylcholine-induced relaxation was impaired in endotoxin-exposed pulmonary arteries, despite a comparable acetylcholine-induced NO release in control arteries. Additionally, NO solution-induced relaxation of endotoxin-exposed arteries was impaired, but could be improved by l-NA or AG. Application of a phosphodiesterase-insensitive cyclic guanosine monophosphate analogue induced similar relaxation in both control and endotoxin-exposed arteries. CONCLUSIONS: Endotoxin-associated NOS2-derived NO is thus associated with impaired NO-mediated relaxation, but does not underlie reduced receptor-mediated pulmonary contractile responses. An increased phosphodiesterase activity may underlie the former, so this route can be explored to replace or improve the effect of inhalational NO therapy in severe sepsis-induced acute lung injury in patients.

Acetylcholine↗
PubMed2005

Do healthcare professionals think that dry powder inhalers can be used interchangeably?

It is important to assess the attitudes of healthcare professionals to the interchangeable use of dry powder inhalers, as there is the potential for this to occur more frequently in the future. A survey of healthcare professionals in the UK found that 87% were concerned about potential problems arising from prescriptions that do not specify the device to be dispensed, and 46% were aware of actual incidents in which patients received an unfamiliar inhaler, including patient confusion, ineffective inhaler technique and the need to reissue prescriptions. In another survey conducted among 427 primary and secondary care physicians in Germany, Netherlands, UK and USA, one third of the physicians considered the device before considering the chemical entity within a class of treatments and over half the respondents reported problems with the device as one of the main reasons for switching inhaled therapy. In a survey conducted in Australia, Canada, France, Germany and UK, over 90% of the 726 physicians interviewed thought that interchangeable use of dry powder inhalers would have a negative impact on patient compliance and device handling and on willingness to use the inhaler if the patient was not involved in the choice. In total, 79% of physicians thought that substitution of a patient's regular dry powder inhaler with another could have a negative impact on asthma control. The majority of physicians (95%) were opposed to substitution of one dry powder inhaler for another if the pharmacist does not consult the patient or physician. A majority (86%) were concerned that switching between dry powder inhalers would have an adverse impact on workload. Only 9% of physicians thought that dry powder inhalers were interchangeable, with almost eight out of 10 (79%) considering that there should be official recognition that they are not interchangeable. In conclusion, a number of surveys among healthcare professionals have shown that they believe patient involvement in treatment choice to be essential for adherence to therapy. Dry powder inhalers were perceived as different and not interchangeable, with physicians opposed to substitution of one dry powder inhaler by another without consultation with the patient or physician. Consequently, physicians are in favour of official recognition that dry powder inhalers are not interchangeable, with any cost benefits likely to be outweighed by the need for additional consultations and prescriptions.

Administration, Inhalation↗
PubMed2000

Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique.

BACKGROUND: Patient compliance, inhalation devices, and inhalation techniques influence the effectiveness of inhaled medications. METHODS: This article presents the results of a systematic literature review of studies measuring compliance with inhaled corticosteroids, measuring inhalation technique with different inhalation devices, and estimating the proportion of inhaled drug that is deposited in the lung. RESULTS: Overall, patients took the recommended doses of inhaled medication on 20 to 73% of days. Frequency of efficient inhalation technique ranged from 46 to 59% of patients. Education programs have been shown to improve compliance and inhalation techniques. The lung deposition achieved with different inhalers depends on particle size as well as inhaler technique. CONCLUSION: This review demonstrates that multiple factors may come between a prescription of an inhaled corticosteroid and the arrival of that medicine at its target organ, the lung.

Adrenal Cortex Hormones↗
PubMed1995

Asthma in infants and small children.

The wheezy young child is a particularly challenging patient to treat. This article focuses on a diagnostic approach and some of the treatment issues peculiar to this age group. Specifically addressed are (1) the problem of differentiating asthma from wheezy bronchitis in babies and the clinical implications of this; (2) general concepts of treating babies in whom many commonly used drugs are not FDA approved; (3) inhalation therapy, especially the use of metered-dose inhalers with spacers; (4) the standard asthma drugs and their beneficial and adverse effects, with particular reference to inhaled steroids; and (5) the nonpharmacologic management of asthma. A brief discussion of long-term outcome is also included.

Asthma↗
PubMed2005

Deaths from accidental steam inhalation during traditional therapy.

Death from accidental steam inhalation is quite a rare occurrence. Two cases of children who died during the inhalation of superheated steam in a closed room are reported. To our knowledge this is the first case report where children died from the injurious effects of steam while inhaling steam. At autopsy, petechial haemorrhages in brain, lungs, heart, and congestion of epiglottis, congestion and oedema of lungs were seen macroscopically. Microscopically, trachea showed swelling and oedema of mucosa and sub mucosa, focal loss of mucosal epithelium and coagulative necrosis with scanty inflammatory reaction, lungs showed congestion, oedema and haemorrhages. It is considered that these findings caused hypoxia and cause of death in these cases was accidental inhalation of superheated steam. It indicates that mucosa of respiratory tract is vulnerable to the effects of vapors of superheated steam. Moreover it would seem that fatal hypoxia occurs within a few minutes from the effects of inhalation of steam in a closed space.

Accidents, Home↗
PubMed2001

A prospective clinical study on inhaled nitric oxide therapy for neonates in Japan.

BACKGROUND: This is the first report about a prospective clinical investigation to study the efficacy and safety of nitric oxide (NO) inhalation in infants with persistent pulmonary hypertension of the newborn (PPHN) in Japan. METHODS: Patients in the present study had to meet the following entry criteria: (i) they had to be younger than 7 days of age; (ii) they had to have evidence of PPHN as defined by echocardiograph; (iii) they had to have severe systemic hypoxemia under mechanical ventilation at 100% oxygen supplementation; and (iv) they had to have a failure to respond to conventional therapies. Patients were excluded from this trial if they had any of the following: hypoplastic lung, structural cardiac lesions or severe multiple anomalies. RESULTS: Nitric oxide inhalation therapy was performed in 68 infants who had severe PPHN at 18 hospitals between May 1995 and May 1997. At birth, 21 of 68 infants (31%) weighed less than 1,500 g and 39 infants weighed more than 2,500 g. The diagnoses associated with PPHN were as follows: 27 infants had meconium aspiration syndrome, 15 infants had dry lung syndrome, nine infants had congenital diaphragmatic hernia, six infants had respiratory distress syndrome, three infants had pneumonia and eight infants had other diagnoses. The mean oxygenation index (OI) before NO inhalation therapy in 68 infants was 43.2; 55 infants (81%) had good responses. CONCLUSIONS: These results may be valuable for further randomized controlled and double-blind trials in Japan to evaluate whether NO inhalation therapy is more effective than conventional therapy in infants with severe PPHN.

Administration, Inhalation↗
PubMed2002

New and evolving treatment methods for pulmonary metastases.

Treatment strategies other than surgery for pulmonary metastases are needed to improve disease-free and overall survival. Surgical attempts to solve a biologic problem by mechanical means. Alternative treatment may include induction or adjuvant chemotherapy, lung perfusion or regional drug delivery, biologic therapies (inhaled IL-2, biologic modifiers), and potentially, molecular or genetic therapy. Experimental radiofrequency ablation techniques are rarely applicable. Combinations of resection of macrometastases with treatment of occult micrometastases may be best in improving disease-free and overall survival.

Administration, Inhalation↗
PubMed1999

Evaluation of an evidence-based guideline for bronchiolitis.

OBJECTIVE: To describe the effect of implementing an evidence-based clinical practice guideline for the inpatient care of infants with bronchiolitis at the Children's Hospital Medical Center in Cincinnati, Ohio. METHODOLOGY: A multidisciplinary team generated the guideline for infants < or = 1 year old who were admitted to the hospital with a first-time episode of typical bronchiolitis. The guideline was implemented January 15, 1997, and data on all patients admitted with bronchiolitis from that date through March 27, 1997, were compared with data on similar patients admitted in the same periods in the years 1993 through 1996. Data were extracted from hospital charts and clinical and financial databases. They included LOS and use and costs of resources ancillary to bed occupancy. RESULTS: After implementation of the guideline, admissions decreased 29% and mean LOS decreased 17%. Nasopharyngeal washings for respiratory syncytial virus were obtained in 52% fewer patients. Twenty percent fewer chest radiographs were ordered. There were significant reductions in the use of all respiratory therapies, with a 30% decrease in the use of at least 1 beta-agonist inhalation therapy. In addition, 51% fewer repeated inhalations were administered. Mean costs for all resources ancillary to bed occupancy decreased 37%. Mean costs for respiratory care services decreased 77%. CONCLUSIONS: An evidence-based clinical practice guideline for managing bronchiolitis was highly successful in modifying care during its first year of implementation.guideline, bronchiolitis, evidence-based medicine, pediatrics, outcome research.

Administration, Inhalation↗
PubMed1983

Chamber assisted inhalant treatment (CAIR).

An inhalation therapy device which facilitates the use of hand-held inhaler delivered medications in infants and children has been employed on a trial basis with 17 severe asthmatic children. Using patients as their own control, the dependence on medications, office hospital and emergency room facilities before and after administration of therapy with CAIR chamber was compared. An approximate 50% improvement was noted in all parameters studied. Most notably, hospitalizations were decreased by 94% over a study period which represented 104 months of cumulative observation.

Albuterol↗
PubMed2003

Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications.

Research in the area of pulmonary drug delivery has gathered momentum in the last several years, with increased interest in using the lung as a means of delivering drugs systemically. Advances in device technology have led to the development of more efficient delivery systems capable of delivering larger doses and finer particles into the lung. As more efficient pulmonary delivery devices and sophisticated formulations become available, physicians and health professionals will have a choice of a wide variety of device and formulation combinations that will target specific cells or regions of the lung, avoid the lung's clearance mechanisms and be retained within the lung for longer periods. It is now recognized that it is not enough just to have inhalation therapy available for prescribing; physicians and other healthcare providers need a basic understanding of aerosol science, inhaled formulations, delivery devices, and bioequivalence of products to prescribe these therapies optimally.

Administration, Inhalation↗
PubMed1996

Prescribing trends for anti-asthma drugs in Tasmania following the National Asthma Campaign.

In recent years there has been a change in asthma pharmacotherapy, with considerably greater emphasis placed on the use of preventive therapy (inhaled corticosteroids and sodium cromoglycate) and less reliance on bronchodilator therapy. This study examined Tasmanian prescribing trends to determine whether the recommended changes in the treatment of asthma had transpired into practice and to compare the State prescribing trends with national Australian data. Computerized dispensing records, consisting of summarized monthly lists of all drugs dispensed, from almost one-third of all the community pharmacies within the State were retrospectively collected at intervals of 6 months between 1991 and 1994. Anti-asthma drugs were grouped into beta-agonists, inhaled corticosteroids, theophylline, ipratropium bromide and sodium cromoglycate, and quantities were converted to defined daily doses (DDDs)/1000 population/day, by extrapolation to the entire Tasmanian population. The Tasmanian data were compared with estimated national dispensing data for anti-asthma drugs provided by the Drug Utilization Subcommittee of the Pharmaceutical Benefits Advisory Committee. Tasmanian prescribing was generally similar to the national data, with large rises in the prescribing of inhaled corticosteroids (61% increase), ipratropium bromide (138% increase) and sodium cromoglycate (52% increase), and a decline in theophylline usage (43% decrease) over the period of the study. The prescribing of beta-agonists remained fairly stable over the period of the study, while there was a marked decrease in the ratio of dispensed DDDs of beta-agonists: inhaled corticosteroids (from 2.9 to 1.7). The overall usage of anti-asthma medication in Tasmania was found to be significantly higher than the national data for 1991 and 1992, with an April 1994 level of 74.7 DDDs/1000 population/day (an increase of 6% from April 1991). Tasmanian and national prescribing of anti-asthma drugs appears to have changed in line with current management guidelines, with greater emphasis on the use of inhaled corticosteroids. More attention could also be given to the prescribing of anti-allergy preventive drugs.

Anti-Asthmatic Agents↗
PubMed1998

[Aerosol therapy].

Aerosol therapy plays a major role in the diagnosis and treatment of various lung diseases. The aim of inhalation therapy is to deposit a reproducible and adequate dose of a specific drug to the airways, in order to achieve a high, local, clinical effect while avoiding serious systemic side effects. To achieve this goal, it is therefore important to have an efficient inhalation device to deliver different medications. However, the currently available therapeutic inhalation devices (nebuliser, pressurised metered-dose inhaler and dry powder inhaler) are not very efficient in aerosol delivery and have several disadvantages. Inhalation devices can be assessed by in vitro studies, filter studies and radiolabelled deposition studies. Several radiolabelled deposition studies have shown that nebulisers and pressurised metered-dose inhalers are not very efficient in aerosol delivery. In children, before 1997, only 0.5% to 15% of the total nebulised or actuated dose from a nebuliser or pressurised metered-dose inhaler actually reached the lungs. These numbers were somewhat improved in adults, 30% of the total nebulised or actuated dose reaching the airways. Aerosol therapy with dry powder inhalers was the most efficient before 1997, 30% of the total dose being deposited in the lungs of adults and children. In 1997, new developments in pressurised metered-dose inhalers much improved their efficiency in aerosol delivery. Lung deposition can be increased by up to 60% with use of a non-electrostatic holding chamber and/or a pressurised metered-dose inhaler with a hydrofluoroalkane propellant possessing superior aerosol characteristics. Several studies comparing the clinical efficiency of different inhalation devices have shown that the choice of an optimal inhalation device is crucial. In addition to the aerosol characteristics, ventilation parameters and airway morphology have an important bearing on deposition patterns. These parameters may be greatly influenced by the patient's acceptance of a specific inhalation device and therefore determine the choice of the device used. It is important for the clinical impact to develop more efficient inhalation devices, which need to be assessed for use in different age groups. These devices should be cheap, easy to use, portable, usable with all medications and environmentally safe.

Adult↗
PubMed1983

Nasal inhalation as a cause of inefficient pulmonal aerosol inhalation technique in children.

In order to evaluate whether children can be taught the efficient use of a pressurized terbutaline aerosol with a tube spacer 71 children were given careful instruction in aerosol inhalation technique according to the manufacturer's instructions. Inhalation technique was assessed as being efficient when a child achieved an increase of more than 19% in FEV1 10 min after taking two puffs of terbutaline (each puff = 0.25 mg). After instruction about 37% of children aged 5-7 years and about 80% of children over 7 years were efficient in inhalation technique. Inhalation through the nose after actuation into the mouth accounted for about 50% of treatment failures, with the problem being more frequent in the younger age group. When this error was corrected about 83% of the children were efficient in the technique. Coordination problems and too rapid inspiration after actuation were also common errors. The findings stress the importance of checking all children's inhalation technique before prescribing inhalation therapy. Careful instruction was not enough. The possibility of nasal inhaling should be borne in mind when looking for causes of treatment failure.

Administration, Intranasal↗
PubMed2000

Sustaining the implementation of an evidence-based guideline for bronchiolitis.

OBJECTIVE: To describe the changes occurring over a 3-year period after implementation of an evidence-based clinical practice guideline for the care of infants with bronchiolitis. DESIGN: Before and after study. SETTING: Children's Hospital Medical Center, Cincinnati, Ohio. PATIENTS: Infants 1 year or younger admitted to the hospital with a first-time episode of typical bronchiolitis. INTERVENTION: The guideline was implemented January 15, 1997. Data on all patients discharged from the hospital with bronchiolitis, from January 15 through March 27, in 1997, 1998, and 1999, were stratified by year and compared with data on similar patients discharged from the hospital in the same periods in the years 1993 through 1996. MAIN OUTCOME MEASURES: Patient volumes, length of stay for admissions, and use of specific laboratory and therapeutic resources ancillary to bed occupancy. RESULTS: After implementation of the guideline, admissions decreased 30% and mean length of stay decreased 17% (P<.001). Nasopharyngeal washings for respiratory syncytial virus were obtained in 52% fewer patients (P<.001); 14% fewer chest x-ray films were ordered (P<.001). There were significant reductions in the use of all respiratory therapies, with a 17% decrease in the use of at least 1 beta(2)-agonist inhalation therapy (P<.001). In addition, 28% fewer repeated inhalations were administered (P<.001); mean costs for all resources ancillary to bed occupancy fell 41% (P<.001); and mean costs for respiratory care services fell 72% (P<.001). CONCLUSIONS: An evidence-based clinical practice guideline for the care of patients encountered in major pediatric care facility has been successfully sustained beyond the initial year of its introduction to practitioners in southwest Ohio.

Algorithms↗
PubMedDate not supplied

Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease--2003.

Chronic obstructive pulmonary disease (COPD) is a common cause of disability and death in Canada. Moreover, morbidity and mortality from COPD continue to rise, and the economic burden is enormous. The main goal of the Canadian Thoracic Society (CTS) Evidence-Based Guidelines is to optimize early diagnosis, prevention and management of COPD in Canada. Targeted spirometry is strongly recommended to expedite early diagnosis in smokers and exsmokers who develop respiratory symptoms, and who are at risk for COPD. Smoking cessation remains the single most effective intervention in accordance with the increasing severity of symptoms and disability. Long-acting anticholinergics and beta2-agonist inhalers should be prescribed for patients who remain symptomatic despite short-acting bronchodilatory therapy. Inhaled steroids should not be used as first-line therapy in COPD but have a role in preventing exacerbations in patients with more advanced disease who suffer recurrent exacerbations. Management strategies consisting of combined modern pharmacotherapy and nonpharmacotherapeutic interventions (eg, pulmonary rehabilitation/exercise training) can effectively improve symptoms, activity levels and quality of life, even in patients with severe COPD. Acute exacerbations of COPD cause significant morbidity and mortality and should be treated promptly with bronchodilators and a short course of oral steroids; antibiotics should be prescribed for purulent exacerbations. Patients with advanced COPD and respiratory failure require a comprehensive management plan that incorporates structured end-of-life care.

Canada↗